Time-in-range derived from self-measured blood glucose in people with type 2 diabetes advancing to iGlarLixi: a participant-level pooled analysis of three phase 3 LixiLan randomized controlled trials

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F24%3A00085066" target="_blank" >RIV/00023001:_____/24:00085066 - isvavai.cz</a>

Výsledek na webu

<a href="https://dom-pubs.pericles-prod.literatumonline.com/doi/epdf/10.1111/dom.15811" target="_blank" >https://dom-pubs.pericles-prod.literatumonline.com/doi/epdf/10.1111/dom.15811</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/dom.15811" target="_blank" >10.1111/dom.15811</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Time-in-range derived from self-measured blood glucose in people with type 2 diabetes advancing to iGlarLixi: a participant-level pooled analysis of three phase 3 LixiLan randomized controlled trials

Popis výsledku v původním jazyce

AimTo evaluate the efficacy of a fixed-ratio combination of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) in people with type 2 diabetes (T2D) using derived time-in-range (dTIR). MethodsParticipant-level data from LixiLan-L, LixiLan-O and LixiLan-G were pooled and dTIR (70-180 mg/dL), derived time-above-range (&gt; 180 mg/dL) and derived time-below-range (dTBR; &lt; 70 mg/dL) were calculated from participant seven-point self-monitored blood glucose profiles. ResultsThis pooled analysis included data from 2420 participants receiving iGlarLixi (n = 1093), iGlar (n = 836), Lixi (n = 234) or a glucagon-like peptide-1 receptor agonist (GLP-1 RA) (n = 257). Numerically greater improvements in least square (LS) means dTIR were seen from baseline to end of treatment (EOT) with iGlarLixi (25.7%) versus iGlar (15.8%), Lixi (11.7%) or GLP-1 RA (16.2%). At EOT, the mean (standard deviation) dTBR was 0.71% +/- 3.4%, 0.61% +/- 3.2%, 0.08% +/- 1.0% and 0.0% +/- 0.0% for iGlarLixi, iGlar, Lixi and GLP-1 RA, respectively. In a subgroup analysis, participants aged younger than 65 years (n = 1690) and 65 years or older (n = 713) showed numerically greater improvements in LS means dTIR from baseline to EOT with iGlarLixi versus iGlar, Lixi or GLP-1 RA. ConclusionsiGlarLixi achieved improvements in dTIR, with low dTBR values, providing further evidence to inform clinical outcomes with the use of iGlarLixi.

Název v anglickém jazyce

Time-in-range derived from self-measured blood glucose in people with type 2 diabetes advancing to iGlarLixi: a participant-level pooled analysis of three phase 3 LixiLan randomized controlled trials

Popis výsledku anglicky

AimTo evaluate the efficacy of a fixed-ratio combination of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) in people with type 2 diabetes (T2D) using derived time-in-range (dTIR). MethodsParticipant-level data from LixiLan-L, LixiLan-O and LixiLan-G were pooled and dTIR (70-180 mg/dL), derived time-above-range (&gt; 180 mg/dL) and derived time-below-range (dTBR; &lt; 70 mg/dL) were calculated from participant seven-point self-monitored blood glucose profiles. ResultsThis pooled analysis included data from 2420 participants receiving iGlarLixi (n = 1093), iGlar (n = 836), Lixi (n = 234) or a glucagon-like peptide-1 receptor agonist (GLP-1 RA) (n = 257). Numerically greater improvements in least square (LS) means dTIR were seen from baseline to end of treatment (EOT) with iGlarLixi (25.7%) versus iGlar (15.8%), Lixi (11.7%) or GLP-1 RA (16.2%). At EOT, the mean (standard deviation) dTBR was 0.71% +/- 3.4%, 0.61% +/- 3.2%, 0.08% +/- 1.0% and 0.0% +/- 0.0% for iGlarLixi, iGlar, Lixi and GLP-1 RA, respectively. In a subgroup analysis, participants aged younger than 65 years (n = 1690) and 65 years or older (n = 713) showed numerically greater improvements in LS means dTIR from baseline to EOT with iGlarLixi versus iGlar, Lixi or GLP-1 RA. ConclusionsiGlarLixi achieved improvements in dTIR, with low dTBR values, providing further evidence to inform clinical outcomes with the use of iGlarLixi.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30202 - Endocrinology and metabolism (including diabetes, hormones)

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Diabetes, obesity and metabolism

ISSN

1462-8902

e-ISSN

1463-1326

Svazek periodika

26

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

10

Strana od-do

5046-5055

Kód UT WoS článku

001308397300001

EID výsledku v databázi Scopus

2-s2.0-85203326956